Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant

New Microbiologica

Volumn 36, Issue 2, 2013, Pages 145-151

  Cargnelutti, Diego E ^a   Sanchez, María V ^a   Alvarez, Paula ^a   Boado, Lorena ^a   Mattion, Nora ^a   Scodeller, Eduardo A ^a  

^a CCT Mendoza Argentina ^*  (Argentina)

Author keywords

Influenza virus; Recombinant nucleoprotein; Ribi Adjuvant System; Th1 immune responses

Indexed keywords

CELL WALL SKELETON; CORD FACTOR; CORE PROTEIN; DRUG DERIVATIVE; GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 4; LIPID A; NP PROTEIN, INFLUENZA A VIRUS; RIBI ADJUVANT; RNA BINDING PROTEIN; VIRUS ANTIBODY;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFLUENZA; MOUSE; TH1 CELL; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; CELL WALL SKELETON; CORD FACTORS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; LIPID A; MICE; MICE, INBRED BALB C; RNA-BINDING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; VIRAL CORE PROTEINS;

MUS; ORTHOMYXOVIRIDAE;

EID: 84878841571     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. AGGER E.M., ROSENKRANDS I., HANSEN J., BRAHIMI K., VANDAHL B.S., AAGAARD C., ET AL. (2008). Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One. 8, e3116.
2. BAI Y., YE L., TESAR D.B., SONG H., ZHAO D., BJÖRKMAN P.J., ET AL. (2011). Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proc. Natl. Acad. Sci. USA. 8, 108.
3. BERTHOUD T.K., HAMILL M., LILLIE P.J., HWENDA L., COLLINS K.A., EWER K.J., ET AL. (2011). Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 52, 1-7.
4. CARGNELUTTI D.E., SANCHEZ M.V., ALVAREZ P., BOADO L., GLIKMANN G., MATTION N., SCODELLER E.A. (2012). Improved immune response to recombinant influenza nucleoprotein formulated with ISCOMA-TRIX. J. Microbiol. Biotechnol. 22, 416-421.
5. CHAITRA M.G., NAYAK R., SHAILA M.S. (2007). Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant. Vaccine. 10, 7168-7176.
6. COFFMAN R.L., SEYMOUR B.W., LEBMAN D.A., HIRAKI D.D., CHRISTIANSEN J.A., SHRADER B., ET AL. (1988). The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev. 102, 5-28.
7. COLER R.N., SKEIKY Y.A., BERNARDS K., GREESON K., CARTER D., CORNELLISON C.D., ET AL. (2002). Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70, 4215-4225.
8. CONSTANT S.L. AND BOTTOMLY K. (1997). Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 15, 297-322.
9. DAVIDSEN J., ROSENKRANDS I., CHRISTENSEN D., VANGALA A., KIRBY D., PERRIE Y., ET AL. (2005). Characterization of cationic liposomes based on dimethyl-dioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim. Biophys. Acta. 10, 22-31.
10. DREDGE K., MARRIOTT J.B., TODRYK S.M., DALGLEISH A.G. (2002). Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer. Immunol. Immunother. 51, 521-531.
11. EPSTEIN S.L. (2006). Prior H1N1 influenza infection and susceptibility of Cleveland family study participants during the H2N2 pandemic of 1957: an experiment of nature. J. Infect. Dis. 193, 49-53.
12. FOMSGAARD A., KARLSSON I., GRAM G., SCHOU C., TANG S., BANG P., ET AL. (2011). Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine. 16, 7067-7074.
13. GUO L., ZHENG M., DING Y., LI D., YANG Z., WANG H., ET AL. (2010). Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Arch. Virol. 155, 1765-1775.
14. JELINEK I., LEONARD J.N., PRICE G.E., BROWN N., MEYER-MANLAPAT A., GOLDSMITH P.K., ET AL. (2011). TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J. Immunol. 15, 2422-2429.
15. JURADO A., CARBALLIDO J., GRIFFEL H., HOCHKEPPEL H.K., WETZEL GD. (1989). The immunomodulatory effects of interferon-gamma on mature B-lymphocyte responses. Experientia. 15, 521-526.
16. KHADER S.A., BELL G.K., PEARL J.E., FOUNTAIN J.J., RANGEL-MORENO J., CILLEY G.E., ET AL. (2007). IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8, 369-377.
17. LAMERE M.W., MOQUIN A., LEE F.E., MISRA R.S., BLAIR P.J., HAYNES L., ET AL. (2011a). Regulation of anti-nucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J. Virol. 85, 5027-5035.
18. LAMERE M.W., LAM H.T., MOQUIN A., HAYNES L., LUND F.E., RANDALL T.D., ET AL. (2011b). Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 1, 4331-4339.
19. MCMICHAEL A.J., MICHIE C.A., GOTCH F.M., SMITH G.L., MOSS B. (1986). Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J. Gen. Virol. 67, 719-726.
20. MILICIC A., KAUR R., REYES-SANDOVAL A., TANG C.K., HONEYCUTT J., PERRIE Y., HILL A.V. (2012). Small cationic DDA: TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses. PLoS One. 7, e34255.
21. PRICE G.E., SOBOLESKI M.R., LO C.Y., MISPLON J.A., QUIRION M.R., HOUSER K.V., ET AL. (2010). Singledose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One. 4, e13162.
22. RAO M., MATYAS G.R., VANCOTT T.C., BIRX D.L., ALVING C.R. (2004). Immunostimulatory CpG motifs induce CTL responses to HIV gp140 oligomeric type I envelope protein. Immunol. Cell. Biol. 82, 523-530.
23. RAVINDRAN R., BHOWMICK S., DAS A., ALI N. (2010). Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis. BMC Microbiol. 24, 181.
24. RIMMELZWAAN G.F., FOUCHIER R.A., OSTERHAUS A.D. (2007). Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18, 529-536.
25. ROBUCCIO J.A., GRIFFITH J.W., CHROSCINSKI E.A., CROSS P.J., LIGHT T.E., LANG C.M. (1995). Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs. Lab. Anim. Sci. 45, 420-426.
26. SCHOENEN H., BODENDORFER B., HITCHENS K., MANZANERO S., WERNINGHAUS K., NIMMERJAHN F., ET AL. (2010). Cutting edge: is essential for recognition mincle and adjuvanticity of the mycobacterial cord factor trehalose and its synthetic analog-dibehenate. J. Immunol. 15, 2756-28760.
27. SIN J.I., KIM J., PACHUK C., WEINER D.B. (2000). Interleukin 7 Can Enhance Antigen-Specific Cytotoxic-T-Lymphocyte and/or Th2-Type Immune Responses In Vivo. Clin. Diagn. Lab. Immunol. 7, 751-758.
28. THUENG-IN K., MANEEWATCH S., SRIMANOTE P., SONGSERM T., TAPCHAISRI P., SOOKRUNG N., ET AL. (2010). Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines. Vaccine. 24, 6765-6777.
29. VANLANDSCHOOT P., MAERTENS G., JOU W.M., FIERS W. (1993). Recombinant secreted haemagglutinin protects mice against a lethal challenge of influenza virus. Vaccine. 11, 1185-1187.
30. WATANABE R., YOO Y.C., HATA K., MITOBE M., KOIKE Y., NISHIZAWA M. ET AL. (1999). Inhibitory effect of trehalose dimycolate (TDM) and its stereoisometric derivatives, trehalose dicorynomycolates, with low toxicity on lung metastasis of tumour cells in mice. Vaccine. 17, 1484-1492.
31. YIP H.C., KARULIN A.Y., TARY-LEHMANN M., HESSE M.D., RADEKE H., HEEGER PS. ET AL. (1999). Adjuvant-guided type-1 and type-2 immunity: infectious/non-infectious dichotomy defines the class of response. J. Immunol. 1, 3942-3949.
32. ZHOU D., WU T.L., LASARO M.O., LATIMER B.P., PARZYCH E.M., BIAN A. ET AL. (2010). A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol. Ther. 18, 2182-2189.